Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors

Sponsor
Spaulding Rehabilitation Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT02896348
Collaborator
(none)
40
1
2
23
1.7

Study Details

Study Description

Brief Summary

The goal of this study is to:
  1. Assess the usability of the SynPhNe device in a home environment.

  2. Evaluate the efficacy of the SynPhNe home use device to improve motor hand function in chronic stroke subjects when used with a few sessions of standard care, as compared to standard care alone.

Condition or Disease Intervention/Treatment Phase
  • Device: SynPhNe platform
  • Other: Conventional therapy
N/A

Detailed Description

The goal of this study is to explore if the SynPhNe system can be used easily at home for people who suffered a stroke. With this study, we are also investigating if the SynPhNe system used could improve your hand function when it is used with a few sessions of research therapy.

SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly via Bluetooth with the computer to provide subject with feedback while performing motor tasks with their hand. The head cap records your brain activity and gives feedback to help relaxing while exercising.

We are combining the use of the device with a research oriented rehabilitation program in a supervised environment. The SynPhNe system has not been approved by the U.S. Food and Drug Administration.

Subjects will be randomized by chance (like a coin toss) to one of the two groups: lab-based upper extremity research therapy alone or lab-based upper extremity research therapy in addition to the SynPhNe system for home-based exercises.

  • The lab-based upper-extremity research therapy in its content is similar to regular occupational therapy and will focus exercise movements of arm and hand.

  • The group testing the SynPhNe system at home will have the system lent at no cost.

The study last for up to 12 weeks and involves up to 22 sessions in total:
  • Up to 3 sessions will be for testing arm movements (at baseline, after research therapy and at 1 month follow-up).

  • 18 research therapy sessions. 10 of them will be done at Spaulding Rehabilitation Hospital with a therapist and 8 of them by yourself, at home. Subjects will either be using the SynPhNe system or use the therapy plan recommended by the therapist, depending on the randomization. Each of these visits will be an hour long. They will be scheduled 3 days per week for six weeks.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors
Anticipated Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: SynPhNe therapy

Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform, over 6 weeks. The sessions will emphasize on the wrist and fingers movements, including functional activities. During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. Over the next 4 to 5 weeks, 10 sessions following exercises prompted by the SynPhNe system will be done unsupervised at home (or under limited supervision at the hospital), 2 sessions will be done at Spaulding Rehabilitation Hospital to review exercises with the SynPhNe system.

Device: SynPhNe platform
SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.

Active Comparator: Conventional therapy

Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The sessions will emphasize on the wrist and fingers movements, including functional activities. During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The remaining 10 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan. Over that time, 2 visits to Spaulding Rehabilitation will be made to review home treatment plan. Over the course of the study, participants will wear GeneActiv sensors to gather information about upper-extremity usage.

Other: Conventional therapy
Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.

Outcome Measures

Primary Outcome Measures

  1. Fugl-Meyer Upper Extremity [Changes from baseline Fugl-Meyer scores at 7 weeks and at one month follow-up]

    FM-UE is a measure of upper-extremity motor impairment including coordination and speed.

  2. Box and Block test [Changes from baseline scores at 7 week and at one month follow-up]

    Gross motor manual dexterity assessment

  3. Wolf Motor Function Test (Upper Extremity) [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    of 17 items that are upper extremity motor tasks and that can assess movement components required for daily tasks.

Secondary Outcome Measures

  1. Jamar dynamometer [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Hand grip strength

  2. Visual Analogue Scale for Pain [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Assessment of pain intensity from 0 (no pain) to 10 (worse pain experienced)

  3. Modified Ashworth Scale [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Measure of spasticity of Upper Extremity, score range from 0 (no spasticity) to 4 (Passive movement no possible)

  4. Systolic and Diastolic Blood Pressure [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Arm measured blood Pressure

  5. Motor Activity Log [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Measure of amount and quality of arm use in daily life

  6. EQ5D questionnaire [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Assessment of Quality of life

Other Outcome Measures

  1. Goniometry - Active Range of Motion [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Upper-extremity range of motion

  2. Manual Muscle Testing (Kendall) [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Muscle strength assessed by a therapist following Kendall guidelines. Scores range from 0 (no contraction) to 5 (maximum strength)

  3. WHO-ICF problem solving form [Changes from baseline scores at Baseline, at 7 weeks and at one month follow-up]

    Identification of participant's problems at the function, activity and environmental factors levels, following the World Health Organization International Classification of Functioning Codes. Decrease in number of problems identified at baseline indicates better outcomes.

  4. Device satisfaction feedback questionnaire (only for intervention group) [Scores at 7 weeks]

    Questionnaire to gather satisfaction feedback about usage of the device. Questions are scored from 1 to 5, total score up to 25. Higher score indicate higher satisfaction with the device.

  5. Number of sessions completed (only for intervention group) [Scores at 7 weeks]

    Log of completed sessions by the software. Higher number indicates better adherence to the intervention.

  6. Number of issues encountered with the device and/or software (only for intervention group) [Scores at 7 weeks]

    Number of occurrences of device and/or software malfunction.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Ischemic or hemorrhagic stroke at least 6 months prior study enrollment ;

  • Moderate upper-extremity hemiparesis (initial score on the Upper Extremity Fugl-Meyer Assessment between 21 and 55 out of 66) ;

  • Ability to extend at least 2 fingers in the affected hand 10 degrees at any joint with pain-free passive range of motion at least 50% in all joints below the elbow.

Exclusion Criteria:
  • Cognitive impairment resulting to inability to follow instructions (as assessed with the MMSE) and inability to sustain attention for more than 10 minutes;

  • Current participation in upper-extremity therapy program;

  • Treatment with Botox injections in the affected arm in the previous 3 months and no planned Botox injections before the end of the study;

  • Poor sitting balance (as assessed with the Berg Balance Test);

  • Aphasia sufficient to limit comprehension and completion of the treatment protocol;

  • No more than moderate impairments in paretic UE sensation, passive range of motion, and pain that would limit ability to engage in therapy;

  • Increased muscle tone as indicated by score of >/= 3 on the Modified Ashworth Scale;

  • Previous diagnosis of dementia;

  • Previous diagnosis of neurological diseases other than Stroke;

  • History of seizures disorder and/or a seizure occuring within the last 6 months;

  • Other conditions affecting function of the stroke affected upper limb;

  • Severe pain in the stroke affected upper limb;

  • Terminal diseases with expected survival <1 year;

  • Not able to provide us or give us access to brain imaging of their Stroke lesion.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Spaulding Rehabilitation Hospital Boston Massachusetts United States 02129

Sponsors and Collaborators

  • Spaulding Rehabilitation Hospital

Investigators

  • Principal Investigator: Paolo Bonato, PhD, Spaulding Rehabilitation Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Paolo Bonato, PhD, Spaulding Rehabilitation Hospital
ClinicalTrials.gov Identifier:
NCT02896348
Other Study ID Numbers:
  • 2016-P-000666
First Posted:
Sep 12, 2016
Last Update Posted:
Sep 27, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Paolo Bonato, PhD, Spaulding Rehabilitation Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 27, 2021